Abstract:Despite the effectiveness of insulin injections in managing hyperglycemia in type 1 diabetes mellitus (T1DM), they fall short in addressing autoimmunity and regenerating damaged islets. This review aims to explore the potential and prospects of emerging treatment modalities for T1DM, including mesenchymal stem cells (MSCs), MSC-derived exosomes, gene therapy, islet allotransplantation, pancreatic islet cell transplantation, and teplizumab. We review emerging treatment modalities for T1DM, highlighting several promising strategies with varied mechanisms and outcomes. Mesenchymal stem cells demonstrate potential in modulating the immune response and preserving or restoring beta-cell function, although variability in sources and administration routes necessitates further standardization. Similarly, MSC-derived exosomes show promise in promoting beta-cell regeneration and immune regulation, supported by early-stage studies showing improved glucose homeostasis in animal models, albeit with limited clinical data. Gene therapy, utilizing techniques like CRISPR-Cas9, offers targeted correction of genetic defects and immune modulation; however, challenges in precise delivery and ensuring long-term safety persist. Islet allotransplantation and pancreatic islet cell transplantation have achieved some success in restoring insulin independence, yet challenges such as donor scarcity and immunosuppression-related complications remain significant. Teplizumab, an anti-CD3 monoclonal antibody, has demonstrated potential in delaying T1DM onset by modulating immune responses and preserving beta-cell function, with clinical trials indicating prolonged insulin production capability. Despite significant progress, standardization, long-term efficacy, and safety continue to pose challenges across these modalities. Conclusion: While these therapies demonstrate significant potential, challenges persist. Future research should prioritize optimizing these treatments and validating them through extensive clinical trials to enhance T1DM management and improve patient outcomes.

Preservation of β-Cells as a Therapeutic Strategy for Diabetes

Therapeutic opportunities for pancreatic β-cell ER stress in diabetes mellitus

From islet transplantation to beta-cell regeneration: an update on beta-cell-based therapeutic approaches in type 1 diabetes

Pancreatic β-cell failure, clinical implications, and therapeutic strategies in type 2 diabetes

Pancreatic -cell failure, clinical implications, and therapeutic strategies in type 2 diabetes

Targeting the pancreatic β-cell to treat diabetes

Targeting β-Cell Plasticity: A Promising Approach for Diabetes Treatment

Advancing diabetes management: Exploring pancreatic beta-cell restoration's potential and challenges

Transcriptional Control of Pancreatic Β-Cell Identity and Plasticity During the Pathogenesis of Type 2 Diabetes.

Targeted Pharmacological Therapy Restores Beta-Cell Function For Diabetes Remission

Β-Cell Dynamics in Type 2 Diabetes and in Dietary and Exercise Interventions

Exploring Novel Treatment Modalities for Type 1 Diabetes Mellitus: Potential and Prospects

Gene therapy targeting key beta cell regulators as a potential intervention for diabetes

Pancreatic Beta Cell Regeneration Induced By Clinical And Preclinical Agents

Benefits and Hurdles of Pancreatic β-Cell Replacement

Harnessing cellular therapeutics for type 1 diabetes mellitus: progress, challenges, and the road ahead

Pancreatic beta‐cell mass and function and therapeutic implications of using antidiabetic medications in type 2 diabetes

Emerging Strategies for Beta Cell Encapsulation for Type 1 Diabetes Therapy

Various Chemical Strategies & Mediators that Improve Beta-Cell Function Through Regeneration and Reprogramming

Cellular Signaling Pathways Regulating Β‑cell Proliferation As a Promising Therapeutic Target in the Treatment of Diabetes (Review)

Future alternative therapies in a quest to halt aberrations in diabetes mellitus.